CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Ixabepilonedrug
Likely dose
10–45 mg/m² IV infusion once every 21 daysAI-extracted
Key inclusion· 4
  • ✓Confirmed diagnosis of a primary solid tumor
  • ✓Measurable or non-measurable disease
  • ✓Progressive disease
  • ✓Age ≥18 years
Key exclusion· 6
  • ✕Women of childbearing potential not using birth control
  • ✕Pregnant or breast-feeding women
  • ✕Positive pregnancy test at enrollment
  • ✕Brain metastases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00162136
NCT00162136Phase 1Completed
CompareCT.gov

Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies

R-Pharm·interventional·Posted Sep 13, 2005·Updated Nov 2, 2020

In Brief

A Phase 1 clinical trial evaluating Ixabepilone for Solid Malignancies. Completed, enrolled 35 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 13, 2005
Enrollment StartSep 1, 2005
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.8 years ago

Interventions

Ixabepilonedrug

Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles